Susquehanna International Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.8M | Buy |
739,400
+7,900
| +1% | +$461K | ﹤0.01% | 1432 |
|
|
2025
Q4 | $43.5M | Buy |
731,500
+103,300
| +16% | +$5.62M | 0.01% | 1480 |
|
|
2025
Q3 | $34M | Buy |
628,200
+204,800
| +48% | +$11.7M | ﹤0.01% | 1673 |
|
|
2025
Q2 | $23.3M | Buy |
423,400
+151,800
| +56% | +$8.94M | ﹤0.01% | 1849 |
|
|
2025
Q1 | $19.2M | Sell |
271,600
-274,100
| -50% | -$18.4M | ﹤0.01% | 1777 |
|
|
2024
Q4 | $35.9M | Buy |
545,700
+26,800
| +5% | +$1.8M | 0.01% | 1365 |
|
|
2024
Q3 | $36.5M | Buy |
518,900
+152,500
| +42% | +$12.7M | 0.01% | 1318 |
|
|
2024
Q2 | $30.2M | Buy |
366,400
+160,200
| +78% | +$13.3M | 0.01% | 1349 |
|
|
2024
Q1 | $18M | Buy |
206,200
+6,300
| +3% | +$564K | ﹤0.01% | 1898 |
|
|
2023
Q4 | $19.3M | Buy |
199,900
+69,500
| +53% | +$6.15M | ﹤0.01% | 1856 |
|
|
2023
Q3 | $11.5M | Buy |
130,400
+62,300
| +91% | +$5.54M | ﹤0.01% | 2372 |
|
|
2023
Q2 | $5.9M | Sell |
68,100
-41,000
| -38% | -$3.86M | ﹤0.01% | 3258 |
|
|
2023
Q1 | $10.6M | Sell |
109,100
-138,800
| -56% | -$14.4M | ﹤0.01% | 2369 |
|
|
2022
Q4 | $25.7M | Buy |
247,900
+21,000
| +9% | +$1.97M | 0.01% | 1320 |
|
|
2022
Q3 | $19.2M | Buy |
226,900
+28,400
| +14% | +$2.53M | 0.01% | 1459 |
|
|
2022
Q2 | $16.4M | Buy |
198,500
+11,800
| +6% | +$940K | ﹤0.01% | 1629 |
|
|
2022
Q1 | $14.4M | Sell |
186,700
-367,600
| -66% | -$30.8M | ﹤0.01% | 2085 |
|
|
2021
Q4 | $49M | Buy |
554,300
+359,100
| +184% | +$29.6M | 0.01% | 1110 |
|
|
2021
Q3 | $15.1M | Sell |
195,200
-164,300
| -46% | -$13M | ﹤0.01% | 2308 |
|
|
2021
Q2 | $30M | Buy |
359,500
+154,500
| +75% | +$12.2M | ﹤0.01% | 1603 |
|
|
2021
Q1 | $15.5M | Sell |
205,000
-51,300
| -20% | -$4.19M | ﹤0.01% | 2195 |
|
|
2020
Q4 | $22.5M | Sell |
256,300
-31,900
| -11% | -$2.53M | ﹤0.01% | 1612 |
|
|
2020
Q3 | $21.9M | Sell |
288,200
-3,400
| -1% | -$344K | ﹤0.01% | 1408 |
|
|
2020
Q2 | $36M | Buy |
291,600
+40,000
| +16% | +$3.98M | 0.01% | 1004 |
|
|
2020
Q1 | $21.3M | Sell |
251,600
-67,500
| -21% | -$5.82M | 0.01% | 1128 |
|
|
2019
Q4 | $27M | Sell |
319,100
-500
| -0.2% | -$37.8K | 0.01% | 1181 |
|
|
2019
Q3 | $21.5M | Buy |
319,600
+5,600
| +2% | +$431K | 0.01% | 1277 |
|
|
2019
Q2 | $26.9M | Buy |
314,000
+12,600
| +4% | +$1.08M | 0.01% | 1082 |
|
|
2019
Q1 | $26.8M | Buy |
301,400
+96,300
| +47% | +$8.93M | 0.01% | 992 |
|
|
2018
Q4 | $17.5M | Buy |
205,100
+27,900
| +16% | +$2.65M | 0.01% | 1163 |
|
|
2018
Q3 | $17.2M | Buy |
177,200
+28,400
| +19% | +$2.83M | 0.01% | 1443 |
|
|
2018
Q2 | $14M | Sell |
148,800
-97,100
| -39% | -$8.5M | ﹤0.01% | 1615 |
|
|
2018
Q1 | $19.9M | Buy |
245,900
+51,400
| +26% | +$4.41M | 0.01% | 1212 |
|
|
2017
Q4 | $17.3M | Sell |
194,500
-8,600
| -4% | -$748K | 0.01% | 1355 |
|
|
2017
Q3 | $18.9M | Buy |
203,100
+17,800
| +10% | +$1.57M | 0.01% | 1267 |
|
|
2017
Q2 | $16.8M | Buy |
185,300
+46,800
| +34% | +$4.26M | 0.01% | 1283 |
|
|
2017
Q1 | $12.2M | Sell |
138,500
-12,500
| -8% | -$1.11M | 0.01% | 1453 |
|
|
2016
Q4 | $12.5M | Sell |
151,000
-11,100
| -7% | -$955K | 0.01% | 1363 |
|
|
2016
Q3 | $15M | Sell |
162,100
-121,700
| -43% | -$11.5M | 0.01% | 1226 |
|
|
2016
Q2 | $22.1M | Sell |
283,800
-40,300
| -12% | -$3.43M | 0.01% | 912 |
|
|
2016
Q1 | $26.7M | Sell |
324,100
-348,100
| -52% | -$28.3M | 0.01% | 808 |
|
|
2015
Q4 | $70.4M | Buy |
672,200
+115,500
| +21% | +$12.1M | 0.03% | 472 |
|
|
2015
Q3 | $58.6M | Sell |
556,700
-14,000
| -2% | -$1.87M | 0.03% | 555 |
|
|
2015
Q2 | $78.1M | Buy |
570,700
+267,900
| +88% | +$33.2M | 0.03% | 489 |
|
|
2015
Q1 | $37.7M | Buy |
302,800
+214,200
| +242% | +$22.7M | 0.02% | 783 |
|
|
2014
Q4 | $8.01M | Sell |
88,600
-256,200
| -74% | -$21.3M | ﹤0.01% | 2267 |
|
|
2014
Q3 | $24.9M | Sell |
344,800
-72,400
| -17% | -$4.76M | 0.01% | 1217 |
|
|
2014
Q2 | $26M | Buy |
417,200
+187,200
| +81% | +$11.3M | 0.01% | 1167 |
|
|
2014
Q1 | $15.7M | Sell |
230,000
-71,600
| -24% | -$5.28M | 0.01% | 1508 |
|
|
2013
Q4 | $21.2M | Buy |
301,600
+156,000
| +107% | +$10.6M | 0.01% | 1292 |
|
|
2013
Q3 | $10.5M | Buy |
145,600
+800
| +0.6% | +$53.2K | 0.01% | 1850 |
|
|
2013
Q2 | $8.08M | Buy |
+144,800
| New | +$9.02M | ﹤0.01% | 2052 |
|
Other funds holding BMRN
VCM
VPM
Susquehanna International Group's BMRN Position: Q1 2026 in Review
Susquehanna International Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 87% in Q1 2026, selling an estimated $7.04M and leaving 18,513 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #7776.
Susquehanna International Group first reported a position in BMRN in Q2 2013 and has held it in 49 quarters since. The position peaked at $59.1M in Q1 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Susquehanna International Group held 18,513 shares of BioMarin Pharmaceuticals worth $1.05M as of Q1 2026.
- Susquehanna International Group sold 120,697 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $7.04M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7776 holding.
- Susquehanna International Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Susquehanna International Group's BioMarin Pharmaceuticals position peaked at $59.1M in Q1 2024.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.